Fig. 4.

Clinical actionability of mutations identified in ovarian clear cell carcinoma specimens. Tier 1 alterations are those with direct clinical implications for a specific tumor type, including therapies approved by the FDA. Tier 2 includes alterations for which FDA-approved therapies exist for other tumor types, as well as investigational therapies, consensus findings from meta-analyses, preclinical studies, and case reports